Craig C. Hopkinson - 18 Feb 2024 Form 4 Insider Report for Alkermes plc. (ALKS)

Role
EVP R&D, Chief Medical Officer
Signature
/s/ Jeffrey Geary, attorney-in-fact for Craig C. Hopkinson
Issuer symbol
ALKS
Transactions as of
18 Feb 2024
Net transactions value
-$266,086
Form type
4
Filing time
21 Feb 2024, 17:32:27 UTC
Previous filing
12 Feb 2024
Next filing
23 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALKS Ordinary Shares Options Exercise +8,897 +10% 96,834 18 Feb 2024 Direct F1
transaction ALKS Ordinary Shares Tax liability $127,143 -3,951 -4.1% $32.18 92,883 18 Feb 2024 Direct
transaction ALKS Ordinary Shares Options Exercise +10,297 +11% 103,180 20 Feb 2024 Direct F1
transaction ALKS Ordinary Shares Tax liability $138,943 -4,572 -4.4% $30.39 98,608 20 Feb 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALKS Restricted Stock Unit Award Options Exercise -8,897 -33% 17,793 18 Feb 2024 Ordinary Shares 8,897 Direct F1, F2
transaction ALKS Restricted Stock Unit Award Options Exercise -10,297 -100% 0 20 Feb 2024 Ordinary Shares 10,297 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one ordinary share.
F2 Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.
F3 Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.